SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Stock Hong Kong S.E.
Equities
2196
CNE100001M79
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.26 HKD | +2.17% |
|
+7.17% | -27.88% |
| Sales 2024 * | 45.05B 6.22B 48.68B | Sales 2025 * | 50.8B 7.01B 54.89B | Capitalization | 54.65B 7.54B 59.04B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.34B 461M 3.61B | Net income 2025 * | 4.28B 590M 4.62B | EV / Sales 2024 * | 1.56 x |
| Net Debt 2024 * | 15.69B 2.17B 16.95B | Net Debt 2025 * | 17.77B 2.45B 19.2B | EV / Sales 2025 * | 1.43 x |
| P/E ratio 2024 * |
18.1
x | P/E ratio 2025 * |
14
x | Employees | 40,370 |
| Yield 2024 * |
1.83% | Yield 2025 * |
2.14% | Free-Float | 63.42% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +2.17% | ||
| 1 week | +7.17% | ||
| Current month | -4.22% | ||
| 1 month | -6.41% | ||
| 3 months | -15.10% | ||
| 6 months | -28.72% | ||
| Current year | -27.88% |
1 week
11.44
12.30
1 month
11.3213.08
Current year
11.3217.18
1 year
11.3223.20
3 years
11.3282.00
5 years
11.3282.00
10 years
11.3282.00
| Managers | Title | Age | Since |
|---|---|---|---|
De Yong Wen
CEO | Chief Executive Officer | 52 | - |
Dong Ming Li
PSD | President | 55 | 20-10-28 |
Yi Fang Wu
CHM | Chairman | 54 | 04-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fang Yao
BRD | Director/Board Member | 54 | 10-04-08 |
Qi Yu Chen
BRD | Director/Board Member | 52 | 94-03-31 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.37% | 4 M€ | -27.92% | ||
| 0.63% | 2 M€ | -18.13% | - | |
| 0.21% | 3 M€ | -2.93% | - | |
| 0.18% | 2 M€ | -14.14% | ||
| 0.16% | 4 M€ | -11.56% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 12.26 | +2.17% | 3 793 008 |
| 24-04-25 | 12 | +1.18% | 3,075,877 |
| 24-04-24 | 11.86 | +0.85% | 2,873,012 |
| 24-04-23 | 11.76 | -0.51% | 2,995,842 |
| 24-04-22 | 11.82 | +3.32% | 4,174,231 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 01:51 am EDT
More quotes
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical group organized around 4 areas of activities:
- research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases;
- sale of medical equipments and diagnosis products (17.3%);
- medical and hospital services (10.5%);
- other (0.1%).
China accounts for 72.9% of net sales.
Sector
Pharmaceuticals
Calendar
2024-04-28
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
22.88
CNY
Average target price
29.75
CNY
Spread / Average Target
+30.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.17% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.45% | 233B | |
| +6.04% | 201B | |
| -10.51% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- 600196 Stock
- 2196 Stock
